Down 36% in 2025, should you buy CSL shares today?

A leading investment expert offers his outlook for CSL's beaten-down share price.

Key points
  • CSL shares have dropped 1.8% today, trading at $180.67, contributing to a significant 35.8% drop for the year.
  • The stock has struggled since an August earnings report revealed disappointing influenza vaccine demand and plans to spin off the CSL Seqirus segment.
  • Analyst Elio D’Amato advises caution, highlighting revenue and profit forecast downgrades for FY 2026 and ongoing pressures from integration and restructuring costs.

CSL Ltd (ASX: CSL) shares are sinking today.

Shares in the S&P/ASX 200 Index (ASX: XJO) biotech stock closed on Friday trading for $183.93. In afternoon trade on Monday, shares are changing hands for $180.67 apiece, down 1.8%.

For some context, the ASX 200 is down 0.6% at this same time.

With today's intraday losses factored in, CSL shares are down a painful 35.8% in 2025. And CSL's dividend payouts won't do much to take the sting out of those losses. The ASX 200 biotech stock currently trades on a 2.5% unfranked trailing dividend yield.

If you've been following along with Australia's third-largest listed company (currently commanding a market cap of just under $88 billion), you'll know that its troubles really began on 19 August.

The stock closed down 16.9% on the day, as investors reacted negatively to the release of CSL's full-year FY 2025 results.

One of the issues that had investors reaching for their sell buttons was the lower-than-expected level of influenza vaccine demand in the United States.

Investors also were caught off guard by management's announcement that the CSL Seqirus segment – one of the world's largest influenza vaccine businesses – was going to be spun off into a separate ASX-listed company.

That plan has since been temporarily put on the back burner as the company waits for improved conditions in the US influenza vaccine market.

Which brings us back to our headline question…

A doctor shrugs and holds his hands out.

Image source: Getty Images

Should you buy the big dip on CSL shares now?

EnviroInvest's Elio D'Amato recently analysed the outlook for the biotech giant's share price (courtesy of The Bull). And he believes there's likely more pain to come before the stock finds solid support.

"I recommended selling CSL in TheBull.com.au in February 2025 after the biotechnology giant posted a lacklustre first half result in fiscal year 2025, in my view," he said.

"The shares have substantially fallen from $261 on February 24. The stock was trading at $178.83 on December 11," D'Amato noted.

And CSL shares certainly weren't helped by management's FY 2026 guidance downgrades.

"CSL recently cut revenue and profit growth forecasts for fiscal year 2026," D'Amato said.

CSL stock closed down 15.9% on 28 October, the day of that announcement. That came after management downgraded CSL's revenue growth guidance to 2% to 3% (from the prior 4% to 5%). And the company's net profit after tax before amortisation (NPATA) growth guidance was reduced to 4% to 7% (from the prior 7% to 10%).

Commenting on his sell recommendation, D'Amato said:

The company's vaccine division Seqirus is under pressure from declining vaccination rates in the United States. Plasma collection remains healthy, but integration costs involving CSL Vifor, a leader in iron deficiency and nephrology, amid restructuring expenses continue to weigh on margins and cash flow, in my view.

D'Amato concluded, "In the absence of near-term catalysts and years of share price stagnation, capital could be better deployed elsewhere until the outlook improves."

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor with stethoscope typing on her computer.
Healthcare Shares

$128 million contract win: Are Pro Medicus shares a strong buy?

I remain a fan of this healthcare technology company, and today's announcement gives me another reason to be optimistic.

Read more »

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »